[Pleiotropic effects of fibric acid derivatives (Lipanthyl-200) among patients with metabolic syndrome].
Zvenigorodskaia
L A
LA
Mel'nikova
N V
NV
Bondarenko
E Iu
EIu
D050260:Carbohydrate Metabolism / Q000187:drug effects; D002995:Clofibric Acid / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications*; D008875:Middle Aged
D000960:Hypolipidemic Agents; D008055:Lipids; D002995:Clofibric Acid; D011345:Fenofibrate